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Abstract: NQO1 (NAD(P)H:quinoneoxidoreductase 1) is a reductive enzyme that is an important activator of bioreductive 
antitumor agents. NQO1 activity varies in individual tumors but is generally higher in tumor cells than in normal cells. NQO1 
has been used as a target for tumor speciﬁ  c drug development. We investigated a series of bioreductive benzoquinone mus-
tard analogs as a model for NQO1 targeted individualized cancer chemotherapy. We compared the tumor cell growth 
inhibitory activity of benzoquinone mustard analogs with sterically bulky groups of different size and placed at different 
positions on the benzoquinone ring, using tumor cell lines with different levels of NQO1. We demonstrated that functional 
groups of different steric size could be used to produce a series of bioreductive antitumor agents that were activated by dif-
ferent levels of NQO1 in tumor cells. This series of drugs could then be used to target cells with speciﬁ  c levels of NQO1 for 
growth inhibition and to avoid damage to normal cells, like bone marrow cells, that have low levels of NQO1. This approach 
could be used to develop new bioreductive antitumor agents for NQO1 targeted individualized cancer chemotherapy.
Keywords: individualized cancer chemotherapy, tumor targeting, bioreductive agents, NQO1, benzoquinone mustard
Introduction
Current anticancer agents are generally potent enough to kill most cancer cells, but their use is limited by 
toxic side effects. Similarities between cancer and normal cells result in a narrow therapeutic index. The use 
of chemotherapy could be greatly enhanced by new drugs that speciﬁ  cally target cancer cells. An important 
strategy to improve selectivity of anticancer drugs for cancer cells is enzyme-directed tumor targeting.
1,2 In 
this strategy drugs activated by a speciﬁ  c enzyme are used to treat tumors with high levels of that enzyme.
Bioreductive agents are a class of anticancer drugs that must be activated in cells by reductive 
enzymes. These agents are preferentially active in solid tumors, which represent the majority of cancers 
and produce the highest mortality. The clinical potential
3,4 and mode of action
5,6 of these agents have 
been actively studied, and the use of the prototype drug mitomycin C (MMC) in the clinic has been 
reviewed.
7 Other agents like porﬁ  romycin, diaziquone (AZQ), 3-hydroxymethyl-5-aziridinyl-1-methyl-
2-(1H-indole-4,7-dione)prop-β-en-α-ol (EO9), tirapazamine (TPZ) and 2,5-diaziridinyl-3-
(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) have been tested clinically,
7–15 and there is 
also ongoing work to develop new agents.
16,17 These drugs are potent antitumor agents, but produce a 
variety of side effects including lung,
7,18 hearing, muscle and renal toxicity.
10,12 However, marrow 
toxicity is often the dose limiting toxicity for these agents.
7,9,10,19 Bioreductive agents can be activated 
by two electron reducing enzymes like NAD(P)H:quinoneoxidoreductase 1 (NQO1; DT-diaphorase)
1,20 
or one electron reducing enzymes like NADPH cytochrome P450 reductase (P450 Red).
5,21
NQO1 is a ﬂ  avoprotein that catalyzes 2-electron reduction of quinones and N-oxides.
1 Several human 
diaphorases are known,
1,22,23 but NQO1 appears to be most important for activating bioreductive agents.
1,22,24 
NQO1 is a homodimer that uses NAD(P)H as an electron donor.
1 The enzyme is mainly cytosolic, but a 
signiﬁ  cant proportion of the enzyme is present in the nucleus of cancer cells.
25 It is ubiquitous in eukaryotes 2
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but levels vary in different tissues,
1,24,26 with low 
levels in hematopoetic cells.
26 Activity is usually 
higher in tumor than normal cells.
24,26,26
NQO1 has been shown to play a role in the 
activation of cancer chemotherapeutic agents,
1,20,28 
detoxiﬁ  cation of xenobiotics
29 and cancer preven-
tion.
20,28 Activation of bioreductive agents by 
NQO1 has been extensively studied.
1,20 Cells with 
elevated NQO1 levels are more sensitive to MMC 
and drug activity is decreased by the NQO1 
inhibitor, dicoumarol.
30–32 Thus, NQO1 is a major 
activating enzyme for MMC. NQO1 is also the 
major activating enzyme for EO9, 2,5-diaziridinyl-
3,6-dimethyl-1,4-benzoquinone (MeDZQ) and 
RH1.
1,4,14,33,34
Bioreductive agents are ideally suited for enzyme-
directed tumor targeting because they must be acti-
vated in cells by reductive enzymes.
1,2 NQO1 has 
been extensively used as a target for this strategy 
because it is found in all tissues,
24,26 and is prefer-
entially expressed in tumor cells.
24,26,27 In addition, 
NQO1 levels are generally low in hematopoetic 
cells.
26 Thus, agents, like RH1, that are selectively 
activated by NQO1,
14 have been developed to target 
tumors with high NQO1 levels and to avoid bone 
marrow toxicity.
Current bioreductive agents have demonstrated 
the potential of this strategy for improved cancer 
chemotherapy; however, a number of problems 
have hindered the development of new targeted 
anticancer agents. To use NQO1 as a target for 
enzyme-directed tumor targeting requires an agent 
speciﬁ  cally activated by NQO1. If the drug is also 
activated by P450 Red, which is found at appre-
ciable levels in hematopoetic cells and other organs, 
this may produce toxic side effects as is seen with 
MMC.
7 However, NQO1 levels vary in individual 
human tumors. Thus, antitumor agents that have a 
high afﬁ  nity for NQO1 may be activated by the 
low levels of this enzyme in marrow cells resulting 
in marrow toxicity, while agents that have a low 
afﬁ  nity for NQO1 may not be fully activated in 
tumors with lower levels of this enzyme resulting 
in a poor tumor response. The former situation is 
illustrated by the observation that RH1, which is 
highly specific for activation by NQO1
14 but 
has very high afﬁ  nity for this enzyme,
35 produces 
signiﬁ  cant marrow toxicity.
19 An example of the 
latter situation is the resistance to MMC observed 
in tumor cells with low levels of NQO1.
30,36,37
Bioreductive agents need a bioreductive ele-
ment that is reduced and a cytotoxic element that 
is activated by this reduction and produces the 
cytotoxic effects. Current bioreductive agents 
generally use quinones or nitrogen-oxides as bio-
reductive elements and alkylating groups like 
aziridines or nitrogen mustards as cytotoxic ele-
ments. Alkylating groups bind to DNA to produce 
DNA crosslinks
1,38,39 leading to cell death by apop-
tosis.
40 Using a series of benzoquinone mustards 
(BM) analogs, we found that sterically bulky 
groups on the benzoquinone ring signiﬁ  cantly 
decreased the rate of reduction of the BM analogs 
by NQO1 and reduced their cytotoxic and DNA 
crosslinking activities.
41,42 This was likely due to 
interference by the bulky groups with the ability 
of the benzoquinone to ﬁ  t into the active site of 
NQO1. The effect of these bulky groups was also 
inﬂ  uenced by the position of the group on the 
benzoquinone ring moiety. Thus, adding an appro-
priate sterically bulky group to the benzoquinone 
structure could decrease the afﬁ  nity for NQO1. 
This would make it more difﬁ  cult to activate the 
new agent in cells with very low levels of NQO1, 
like bone marrow cells, but could still allow activa-
tion in tumor cells with higher levels of this 
enzyme. Since the level of NQO1 in tumors varies 
in different individuals, an anticancer agent with 
the minimum afﬁ  nity for NQO1 to be fully acti-
vated by the level of enzyme in the tumor of a 
patient would provide the maximum antitumor 
effect, while minimizing activation in the marrow 
and the resulting marrow toxicity for that indi-
vidual. This strategy could provide an optimized 
therapeutic index for each patient.
In this study, we investigated a series of BM 
analogs as a model for NQO1 targeted individual-
ized cancer chemotherapy. We compared the tumor 
cell growth inhibitory activity of BM analogs with 
sterically bulky groups of different size and placed 
at different positions on the benzoquinone ring, 
using tumor cell lines with different levels of 
NQO1. We demonstrated that it was possible to 
design bioreductive agents with the appropriate 
NQO1 afﬁ  nity to target tumors with speciﬁ  c levels 
of NQO1.
Materials and Methods
All media, fetal bovine serum and Hank’s balanced 
salt solutions were obtained from Invitrogen 
(Burlington ON). All reagents for the NQO1 activity 
and MTT assays were obtained from Sigma-
Aldrich (St. Louis, MO). The FaDu, HCT116 and 3
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T47D cell lines were obtained from the American 
Type Culture Collection (Rockville, MD). FaDu, 
human pharynx squamous carcinoma cells, 
HCT116, human colon carcinoma cells and T47D, 
human breast ductal carcinoma cells were grown 
in Dulbecco’s modiﬁ  ed Eagle’s medium: Hams 
F12 (1:1) media with 10% fetal bovine serum.
The syntheses of the BM analogs p-MeBM, 
m-MeBM, p-PBM and m-PBM (Fig. 1) have been 
previously reported.
41,42 m-nPrBM was synthesized 
as described below.
For the preparation of the m-nPrBM precursor 
2-n-propylbenzoquinone, benzoquinone (5.184 g, 
48.0 mmol), butyric acid (3.524 g, 40.0 mmol), 
and silver nitrate (1.02 g, 6.0 mmol) in a acetoni-
trile-water mixture (1:1) (200 mL) were heated to 
reﬂ  ux while a solution of 1.0 M ammonium per-
sulfate (48 mL) was added dropwise over 1 h. After 
an additional 1.25 h reﬂ  ux, the mixture was cooled 
to room temperature and solid sodium bicarbonate 
(3.36 g, 40 mmol) was added in portions to neu-
tralize excess butyric acid. The mixture was 
extracted with ethyl ether (3x100 mL) and the ether 
phase washed with 0.5 M sodium bicarbonate, 
brine and dried over anhydrous sodium sulfate. 
The crude mixture was concentrated and dissolved 
in hexanes-ethyl acetate (7:1) (30 mL), and ﬁ  ltered 
through a short column of (50 g) silica gel. Con-
centration afforded the crude product as a yellow 
oil, 3.51 g. A portion of crude mixture (665 mg) 
was chromatographed on silica using hexanes-ethyl 
acetate (7:1), affording pure 2-n-propylbenzoquinone 
(229 mg) as a yellow semi-solid in 24% overall 
yield. NMR (CDCl3): δ 6.69–6.78 (complex, 2H), 
6.57 (m, 1H), 2.40 (t, 2H), 1.55 (sextet, 2H), 0.98 
(t, 3H).
For preparation of m-nPrBM 6-n-propyl-2-
[bis(2-chloroethylamino)]-1,4-benzoquinone 
(Fig. 1), potassium ﬂ  uoride (0.266 g, 4.58 mmol) 
was added at room temperature to a stirred 
suspension of 2-n-propylbenzoquinone (0.229 g, 
1.53 mmol), bis(2-chloroethylamine) hydrochloride 
(0.817 g, 4.58 mmol) and cupric acetate (0.187 g, 
2.29 mmol) in 95% ethanol (6.0 mL). The mixture 
was stirred open to the air but protected from light 
for 69 h. The mixture was ﬁ  ltered with suction 
through a Celite pad to remove copper salts and the 
precipitate washed with ethyl acetate (2 × 10 mL). 
The ﬁ  ltrates were concentrated, and the residue was 
taken up in ethyl acetate (30 mL). The organic 
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Figure 1. Structures of BM analogs.4
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phase was washed with 0.15 M HCl (15 mL), brine, 
and then dried over anhydrous sodium sulfate. 
Concentration, followed by silica chromatography 
using ethyl acetate-hexanes (1:2) afforded the 6-n-
propyl-2-[bis(2-chloroethylamino)]-1,4-benzoqui-
none as a red semi-solid, 0.440 g, 10% yield. 
1H NMR (CDCl3): δ 6.42 (m, 1H), 5.63 (d, 1H, 
J = 2.4 Hz), 3.82–3.78 (m, 4H), 3.74–3.69 (m, 4H), 
2.37 (t, 2H), 1.54 (sextet, 2H), 0.97 (t, 3H); 
13C 
NMR (CDCl3): δ 186.0, 185.6, 149.0, 147.5, 133.0, 
106.0, 54.8, 40.4, 31.2, 21.1, 13.8.
NQO1 activity in the cell lines was deter-
mined as we have previously described
43 using 2, 
6-dichlorophenolindophenol (DCPIP) as the elec-
tron acceptor. The statistical signiﬁ  cance of differ-
ences in the mean values of the NQO1 activities 
in the three cell lines was evaluated using a one-
way analysis of variance.
For cell growth inhibition studies, BM analogs 
were prepared at various concentrations in dimeth-
ylformamide and were added to cells in media. The 
ﬁ  nal concentration of dimethylformamide in the 
cells was 1%. The cells were incubated with the BM 
analog at 37 ºC for 1 h. The cells were washed and 
incubated for 4 cell doublings at 37 °C. Cell growth 
inhibition was determined by 3-(4, 5-dimethylthiazo-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay as we have previously described.
44,45 The 
results are presented as relative absorbance com-
pared with control vs drug concentration curves, 
and as IC50 values (concentration of drug reducing 
the relative absorbance to 0.5) obtained from the 
linear regression lines of the relative absorbance 
vs drug concentration curves for each BM analog. 
The IC50 values for the 5 BM analogs in each 
cell line were compared by one way analysis of 
variance with Student-Newman-Kuels pairwise 
multiple comparison.
Results
Description of the BM analogs 
and cell lines
The synthesis of the benzoquinone mustards, 
p-MeBM, m-MeBM, p-PBM and m-PBM was 
previously reported.
41,42 Here we report the synthesis 
of a new BM analog, m-nPrBM (Fig. 1). p-MeBM 
and p-PBM have functional group substitutions at 
the C5 position of the benzoquinone ring, while 
m-MeBM, m-nPrBM and m-PBM have functional 
group substitution at the C6 position of the ring. 
The relative steric size of the functional groups is 
CH3  CH3CH2CH2  phenyl. The tumor cell 
growth inhibitory effects of the BM analogs in 
human cancer cells with different levels of NQO1 
were studied to determine if the size and position 
of the functional groups could determine the level 
of NQO1 required to activate the analogs.
Tumor cell growth inhibition studies were carried 
out in FaDu human pharynx squamous carcinoma 
cells, HCT116 human colon carcinoma cells or 
T47D human breast carcinoma cells. The mean  ± 
standard error of the mean (SEM) NQO1 activity 
in these cells was 557.6 ± 120.3, 230.4 ± 31.3 and 
39.7 ± 12.1 nmol.min
−1.mg protein
−1, respectively, 
and these activities were statistically different 
(p  0.02) (Fig. 2).
Tumor cell growth inhibition 
by BM analogs
FaDu, HCT116 or T47D cells were treated with 
various concentrations of each BM analog for 1 h 
and tumor cell growth inhibition was determined 
by MTT assay.
44,45 Figure 3 shows the growth inhi-
bition curves for each of the 5 BM analogs in the 
3 tumor cell lines. In all three cell lines, p-MeBM 
had the greatest inhibitory effect while m-PBM 
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Figure 2. NQO1 activity in tumor cell lines. NQO1 activities in FaDu, 
HCT116 and T47D cells were determined as described.
43 Bars rep-
resent the mean ± SEM of 3 or 4 determinations.5
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had the smallest effect. In FaDu cells, the other 3 
BM analogs produced intermediate effects. In 
HCT116 cells, m-MeBM and p-PBM continued 
to produce an intermediate inhibitory effect; 
however, tumor cell growth inhibition by m-
nPrBM was lower and was similar to that pro-
duced by m-PBM. In T47D cells, m-MeBM again 
produced an intermediate tumor cell growth 
inhibitory effect, while p-PBM, m-nPrBM and 
m-PBM all produced lower but similar inhibitory 
effects.
Table 1 shows the IC50 values for the tumor cell 
growth inhibitory effects of the BM analogs in 
FaDU, HCT116 and T47D cells. There were dif-
ferences in the overall sensitivity of the cell lines 
to the BM analogs; however, there were also 
speciﬁ  c differences in the sensitivities of the cell 
lines to individual drugs. In FaDu cells, the relative 
tumor cell growth inhibitory effects of the BM 
analogs were: p-MeBM  m-MeBM = p-PBM  
m-nPrBM  m-PBM. In HCT116 cells, the relative 
inhibitory effects were: p-MeBM  m-MeBM = 
p-PBM  m-nPrBM = m-PBM. While in T47D 
cells, the relative inhibitory effects were: p-
MeBM  m-MeBM  p-PBM = m-nPrBM = m-
PBM. The differences in activities of the different 
analogs in each cell line were statistically signiﬁ  cant 
by one way analysis of variance (p  0.001).
Discussion
We have previously demonstrated that functional 
groups can signiﬁ  cantly inﬂ  uence the reduction 
and activation of BM bioreductive agents by 
NQO1.
41,42 Activation of these agents was 
decreased as the steric size of the functional group 
increased, and this affect was greater when the 
functional group was at the C6 position on the 
benzoquinone ring compared with the C5 position 
of the ring. We made use of these ﬁ  ndings to design 
a series of BM analogs with different afﬁ  nities for 
activation by NQO1, as a model for developing 
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Figure 3. Cell growth inhibition produced by BM analogs in FaDu, HCT116 and T47D cells. Cells were incubated at 37 °C for 1 h with various 
concentrations of each BM analog and cell growth inhibition was determined by MTT assay as we have previously described.
44,45 The results 
are presented as relative absorbance compared with control vs. drug concentration. Points represent the mean ± SEM of 3 or 4 determina-
tions. The lines are linear regression lines.6
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NQO1 targeted individualized cancer chemotherapy. 
The analogs p-MeBM and m-MeBM have small 
methyl functional groups at C5 and C6 of the 
benzoquinone ring, respectively. We expected 
these analogs to be most easily activated by NQO1 
with p-MeBM being activated by a lower level of 
NQO1 activity than m-MeBM. The p-PBM and 
m-PBM analogs have larger phenyl functional 
groups at C5 and C6 of the ring, respectively. We 
expected these analogs to be less easily activated 
by NQO1 than the methyl analogs, with m-PBM 
requiring the highest level of NQO1 activity. The 
m-nPrBM analog has an n-propyl functional group 
at C6 of the benzoquinone ring. This group is 
smaller than the phenyl group and should produce 
a BM analog that is activated by intermediate 
levels of NQO1.
Human tumor cells have varied levels of NQO1 
activity ranging from  10 nmol. min
−1.mg protein
−1 
to  1000 nmol. min
−1.mg protein
−1. In contrast, 
human bone marrow cells generally have a level 
of NQO1 activity  30 nmol. min
−1.mg protein
−1. 
Since bone marrow toxicity is often the dose lim-
iting toxicity for bioreductive agents, an agent that 
is fully activated by the level of NQO1 in the tumor 
but is not activated by the level of NQO1 in bone 
marrow cells would produce little bone marrow 
toxicity and would have the highest therapeutic 
index. If a series of bioreductive agents that were 
activated by different levels of NQO1 were avail-
able, a patient could be treated with an agent that 
was maximally activated by the level of NQO1 in 
their tumor but minimally activated by the level of 
NQO1 in their bone marrow.
To test this hypothesis, we measured tumor cell 
growth inhibition produced by the series of BM 
analogs having different afﬁ  nities for activation by 
NQO1, in human tumor cell lines with a wide range 
of NQO1 activity. FaDu human pharynx squamous 
carcinoma cells had a high level of NQO1 activity, 
557.6 ± 120.3 nmol.min
−1.mg protein
−1, while 
HCT116 human colon carcinoma cells had a level 
of NQO1 activity that was close to the average for 
human tumors, 230.4  ±  31 nmol.min
−1.mg protein
−1 
(Fig. 2). In contrast, T47D human breast carci-
noma cells had a low level of NQO1 activity 
similar to that found in human bone marrow cells, 
39.7 ± 12.1 nmol.min
−1.mg protein
−1.
When we compared the inhibition of tumor cell 
growth produced by the BM analogs in the three 
tumor cell lines we observed a number of signiﬁ  -
cant differences. Looking at the overall activities 
of the BM analogs, the FaDu and HCT116 cells 
appeared to have similar sensitivities to the BM 
analogs as a group, with IC50 values ranging from 
approximately 0.25 to 6.00 μM in both cell lines. 
In contrast, the T47D cells appeared to be overall 
approximately 5-fold more sensitive to these agents 
as a group (Fig. 3, Table 1). These differences likely 
reﬂ  ect general tissue type and/or cell line variations 
in sensitivity to these agents due to differences in 
drug uptake, drug detoxiﬁ  cation, DNA repair, 
induction of apoptosis and activation by other 
enzymes, and are probably not related to activa-
tion of the analogs by NQO1. This suggestion is 
supported by the ﬁ  nding that in relative terms, 
p-MeBM had the largest growth inhibitory effect; 
m-PBM had the smallest inhibitory effect, and the 
other BM analogs had intermediate inhibitory 
effects in all three cell lines.
When we examined the growth inhibitory 
activities of the ﬁ  ve BM analogs within each cell 
line, we observed signiﬁ  cant differences in the 
relative activity of the analogs in the different cell 
lines. In the FaDu cells with the highest NQO1 
activity, the relative tumor cell growth inhibitory 
Table 1. Tumor cell growth inhibition by BM analogs in cell lines with different NQO1 activities.
IC50 (μM)
BM analog FaDu (n)
1 HCT116 (n)
1 T47D (n)
1
p-MeBM 0.30 ± 0.08 (4) 0.22 ± 0.01 (3) 0.08 ± 0.01 (4)
m-MeBM 1.27 ± 0.13 (4) 2.69 ± 0.25 (4) 0.39 ± 0.04 (4)
p-PBM 1.39 ± 0.31 (4) 1.85 ± 0.13 (3) 0.63 ± 0.08 (4)
m-nPrBM 3.10 ± 0.95 (4) 6.10 ± 1.18 (4) 0.80 ± 0.08 (4)
m-PBM 5.77 ± 1.31 (4) 6.68 ± 1.53 (3) 0.76 ± 0.02 (3)
1Mean ± SEM.
n = number of determinations.7
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activity was p-MeBM  m-MeBM = p-PBM  
m-nPrBM  m-PBM. This suggests that p-MeBM 
was most activated; m-MeBM and p-PBM were 
substantially activated; m-nPrBM was somewhat 
activated, and m-PBM was poorly activated by the 
level of NQO1 in these cells. This is consistent with 
our hypothesis based on the steric size and location 
of the functional groups. In the HCT116 cells with 
an intermediate level of NQO1 activity, the relative 
inhibitory activity was p-MeBM  m-MeBM = 
p-PBM  m-nPrBM = m-PBM, suggesting that 
p-MeBM was most activated; m-MeBM and p-
PBM were substantially activated, and m-nPrBM 
and m-PBM were poorly activated by the level of 
NQO1 in these cells. This represents a decrease in 
the relative growth inhibitory effect of m-nPrBM 
in the HCT116 cells compared with the FaDu cells. 
This suggests that the n-propyl functional group at 
the C6 position produces a greater steric effect than 
the methyl group at the C6 position and the phenyl 
group at the C5 position. In addition, this result 
suggests that m-nPrBM would not be fully acti-
vated in tumors with intermediate levels of NQO1 
and would only be maximally effective in tumors 
with high levels of NQO1 activity. In T47D cells 
with the lowest NQO1 activity, the relative growth 
inhibitory activity was p-MeBM  m-MeBM  
p-PBM = m-nPrBM = m-PBM, suggesting that 
p-MeBM was most activated; m-MeBM was sub-
stantially activated, and p-PBM, m-nPrBM and 
m-PBM were poorly activated by the level of 
NQO1 in these cells. This represents a decrease in 
the relative growth inhibitory effect of p-PBM in 
T47D cells compared with HCT116 cells. This 
result suggests that p-PBM would not be fully 
activated in tumors with low levels of NQO1 and 
would only be effective in tumors with average or 
higher NQO1 activity. Furthermore, these ﬁ  ndings 
indicate that m-MeBM and p-MeBM are at least 
partially activated in cells with low levels of NQO1 
activity like bone marrow cells, and would likely 
produce some bone marrow toxicity.
Since m-nPrBM and p-PBM showed good 
tumor cell growth inhibition in the FaDu cells but 
poor activity in the T47D cells, these BM analogs 
would likely have good antitumor activity in 
tumors with high NQO1 activity but little activity 
in bone marrow cells. Because p-PBM also showed 
good growth inhibition in HCT116 cells, it would 
likely also have good antitumor activity in tumors 
with average levels of NQO1, again with little bone 
marrow toxicity. Thus, m-nPrBM or p-PBM might 
be suitable agents for use in patients having tumors 
with high NQO1; p-PBM might be suitable for use 
in patients having tumors with average NQO1, and 
m-MeBM might be used in patients having tumors 
with low NQO1. However, the use of m-MeBM 
would likely result in at least some bone marrow 
toxicity. The use of p-MeBM would likely produce 
signiﬁ  cant bone marrow toxicity in most patients. 
These results demonstrate the potential of using a 
series of bioreductive agents with different afﬁ  ni-
ties for activation by NQO1 for targeted individu-
alized cancer chemotherapy. They also suggest that 
using functional groups of varying steric size with 
quinone based bioreductive agents represents a 
feasible approach to designing new agents with a 
range of afﬁ  nities for activation by NQO1.
In summary this study has demonstrated that 
functional groups of different steric size can be used 
to produce a series of bioreductive antitumor agents 
that are activated by different levels of NQO1 in 
tumor cells. A series of drugs of this type might be 
used to target cells with speciﬁ  c levels of NQO1 for 
growth inhibition and to avoid damage to normal 
cells, like bone marrow cells, that have low levels of 
NQO1. This approach could be used to develop new 
bioreductive antitumor agents for NQO1 targeted 
individualized cancer chemotherapy that produce 
the optimal therapeutic index for each patient.
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